OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OncoCyte's (OCX) CEO Ronnie Andrews on Q3 2021 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates

DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment

Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know

U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe

Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection

IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that it will release its financial and operating results for the third quarter ended September 30, 2021, on Tuesday, November 9, 2021, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, November 9, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the appointment of Gisela A. Paulsen, MPharm, to the role of Chief Operating Officer (COO). Paulsen brings with her over two decades of experience as a cross-functional leader, with an extensive scientific and operational background leading large-scale global change management and driving commercial and drug development innovation at global pharmaceutical and diagnostics companies.

Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient's response to immunotherapy Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient's response to immunotherapy

Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer

KULR Technology Group

Tuesday Morning Corp

Penny stocks climbing higher even with stocks down today. The post Why Stocks Are Down Today & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Stocks Are Down Today & 3 Penny Stocks To Watch Now

Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response

Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, announced today that Modern Healthcare had selected it as one of the 2021 Best Places to Work in Healthcare. The complete list of this year's winners, in alphabetical order, is available at ModernHealthcare.com/bestplaceslist. Modern Healthcare will publish a special supplement featuring a ranked list of all the winners along with the September 20 issue of Modern Healthcare.

Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate in one-on-one and group investor meetings at the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference.

Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock?

P redictive A ssay for D ecision M aking in A djuvant T herapy (PADMA) Registry to enroll more than 1,000 patients at 25 major hospitals treating lung cancer in the United States beginning Q4 2021

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

Oncocyte Corporation's (NASDAQ: OCX) Q2 revenues were $2.03 million, compared to $143,000 in Q2 FY20 and beating consensus of $1.57 million. Most revenues were attributable to tech transfer under a December licensing deal with Burning Rock Biotech for Oncocyte's DetermaRx lung cancer test.

Oncocyte Shares Fall On Posting Wider Than Expected Q2 Loss

Oncocyte Corporation (OCX) CEO Ronnie Andrews on Q2 2021 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of 0.00% and 23.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q2 Loss, Tops Revenue Estimates

DetermaRx Q2 Sample Volume Grows 23% over Q1 2021

Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update

IRVINE, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate at two upcoming investor conferences.

Oncocyte to Participate in Upcoming Investor Events

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that it will release its financial and operating results for the second quarter ended June 30, 2021, on Tuesday, August 10, 2021, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

Bed Bath & Beyond

Disney

Enterprise Products Partners

Fiverr

IZEA

Lockheed Martin

Osisko Gold Royalties

Walgreens

After the end of the second quarter, let's take a look at where things stand in the InvestorPlace Best Stocks for 2021 contest. The post 10 Best Stocks for 2021: Where Do Things Stand Halfway Through the Year?

10 Best Stocks for 2021: Where Do Things Stand Halfway Through the Year?

Cardiff Oncology

Catalent

Novocure

PerkinElmer

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

RENO, Nev.--(BUSINESS WIRE)--Echelon Diagnostics and Oncocyte join forces to develop analytical software that can scale to support Oncocyte's clinical tests and solutions

EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte's DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2021 Results - Earnings Call Transcript

News for OncoCyte Stock (OCX)